Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

This publication has 24 references indexed in Scilit:

• Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine☆
  Vaccine, 2006
• The Clinical-Grade 42-Kilodalton Fragment of Merozoite Surface Protein 1 ofPlasmodium falciparumStrain FVO Expressed inEscherichia coliProtectsAotus nancymaiagainst Challenge with Homologous Erythrocytic-Stage Parasites
  Infection and Immunity, 2005
• Roll Back Malaria: a failing global health campaign
  BMJ, 2004
• Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-142 malaria vaccine
  Molecular and Biochemical Parasitology, 2003
• Malaria and anemia
  Current Opinion in Hematology, 2003
• The economic and social burden of malaria
  Nature, 2002
• New World monkey efficacy trials for malaria vaccine development: critical path or detour?
  Trends in Parasitology, 2001
• Clinical Immunity to Plasmodium falciparum Malaria Is Associated with Serum Antibodies to the 19-kDa C-Terminal Fragment of the Merozoite Surface Antigen, PfMSP-l
  The Journal of Infectious Diseases, 1996
• Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum
  Molecular and Biochemical Parasitology, 1995
• The major merozoite surface protein as a malaria vaccine target
  Parasitology Today, 1993